High-throughput in vitro profiling assays: lessons learnt from experiences at Novartis.
about
Direct inhibitors of InhA are active against Mycobacterium tuberculosis.A Cryptosporidium PI(4)K inhibitor is a drug candidate for cryptosporidiosis.Maximising use of in vitro ADMET tools to predict in vivo bioavailability and safety.Indolcarboxamide is a preclinical candidate for treating multidrug-resistant tuberculosis.Predictions of the physicochemical properties of amino acid side chain analogs using molecular simulation.Relating Essential Proteins to Drug Side-Effects Using Canonical Component Analysis: A Structure-Based Approach.
P2860
High-throughput in vitro profiling assays: lessons learnt from experiences at Novartis.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
High-throughput in vitro profiling assays: lessons learnt from experiences at Novartis.
@ast
High-throughput in vitro profiling assays: lessons learnt from experiences at Novartis.
@en
type
label
High-throughput in vitro profiling assays: lessons learnt from experiences at Novartis.
@ast
High-throughput in vitro profiling assays: lessons learnt from experiences at Novartis.
@en
prefLabel
High-throughput in vitro profiling assays: lessons learnt from experiences at Novartis.
@ast
High-throughput in vitro profiling assays: lessons learnt from experiences at Novartis.
@en
P2093
P2860
P356
P1476
High-throughput in vitro profiling assays: lessons learnt from experiences at Novartis.
@en
P2093
Alfred Zimmerlin
Bernard Faller
Dejan Bojanic
Jacques Hamon
Jianling Wang
Kamal Azzaoui
Laszlo Urban
Leslie Bell
Steven Whitebread
P2860
P304
P356
10.1517/17425255.2.6.823
P407
P577
2006-12-01T00:00:00Z